Dianthus (DNTH) Therapeutics announced the appointment of John King as Chief Commercial Officer. King brings more than 25 years of global commercial leadership experience within biotechnology, including complement inhibitor experience in neuromuscular and hematological rare diseases. In this newly created position, King will play a critical role in the Company’s corporate and commercial strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.